RESVERLOGIX

TSX: RVX

Resverlogix 2021 Clinical and Commercialization Update

December 16th 2021



Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation may include forward looking information relating to the Phase 3 BETonMACE2 clinical trial, Covid-19, vascular cognitive dementia, chronic kidney disease, fabry disease and pulmonary arterial hypertension clinical trials, and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Donald McCaffrey
Email: don@resverlogix.com
Phone: 587-390-8887
Website: www.resverlogix.com

Key Investment Highlights

Apabetalone is a **first-in-class Phase III asset** with a demonstrated cardio-protective benefit in high-risk Cardiovascular, Diabetic and Kidney patients – utilizing advanced epigenetics to regulate expression of **multiple disease-associated genes**

FDA- Breakthrough Therapy Designation has already been awarded to apabetalone involving prevention of Major Adverse Cardiovascular Events (MACE) in patients, demonstrating a critical ability to obtain expedited regulatory approval for a lead indication

FDA endorsement was based on a Phase III study in which apabetalone demonstrated up to **a 63% hazard reduction, with a P-value of p=0.0002**, in MACE and hospitalization for Congestive Heart Failure (CHF) in high-risk CVD patients

Numerous pandemic related publications, **including Cell and Nature,** have highlighted apabetalone's dual anti-viral and anti-inflammatory approach as having extremely high potential as a significant COVID-19 therapeutic

Resverlogix and **EVERSANA, a pioneers in next generation commercialization services**, have partnered to commercialize apabetalone for COVID-19 with sales/revenue expected in 2022 thus advancing Apabetalone commercialization by 2-3 years

COVID-19 clinical trials have commenced! In April 2021 **Health Canada granted Resverlogix approval** to commence a clinical trial designed to demonstrate apabetalone's potential to reduce hospitalizations and severe illness

Development Pipeline Overview



[1] High-Risk CKD indication defined as patients with T2DM, High-Risk Chronic Kidney Disease (“CKD”), Cardiovascular Disease (“CVD”), and Low HDL-C
[2] Led by academic collaborators at Quebec Heart and Lung Institute, Laval University | Pulmonary Arterial Hypertension (“PAH”)

High-risk Cardiovascular Disease Clinical Results, Updates and Plans

FDA Approves Breakthrough Therapy Designation for Apabetalone

As the result of very safe and promising data the FDA granted Resverlogix the coveted **Breakthrough Therapy Designation**

RESVERLOGIX

U.S. FOOD & DRUG ADMINISTRATION

IND 76487

GRANT –
BREAKTHROUGH THERAPY DESIGNATION

Resverlogix Corp.
Attention: Barry Calvarese
Consultant, Regulatory Affairs
44 Montgomery Street, Suite 4010
San Francisco, CA 94104

Dear Mr. Calvarese:

Please refer to your investigational new drug application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for apabetalone (RVX000222).

We also refer to your December 4, 2019, request for Breakthrough Therapy designation. We have reviewed your request and have determined that apabetalone, in

→ "A **breakthrough therapy designation** is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies."

--FDA Website

Compelling Efficacy of Combining Apabetalone With SGLT2 / DPP4 Inhibitors





Key Takeaways

- Co-administration of apabetalone and SGLT2 or DPP4 inhibitors illustrated a significant reduction of events compared to placebo and SGLT2 or DPP4 inhibitors
  - Quantified by MACE and hospitalization for congestive heart failure (CHF)
- Provides compelling market opportunity with SGLT2/DPP4 inhibitors forecasted to have $25 billion global market value

Source: RVX Internal Analysis January 2020

Top standard of care includes: high intensity statins, ACE inhibitors/angiotensin II blockers, beta blockers, antiplatelet agents

Confirmed Efficacy for Treatment of High-Risk CKD Patients



No. at Risk				
Placebo	164	128	85	19
Apabetalone	124	110	73	17



Key Takeaways

- Apabetalone significantly reduced the risk of MACE and CHF with a 50% hazard reduction
- CKD patients are at high risk of poor cardiovascular outcomes and have a strong unmet need, despite current standard of care

Source: RVX Internal Analysis January 2020

Top standard of care includes: high intensity statins, ACE inhibitors/angiotensin II blockers, beta blockers, antiplatelet agents

BETonMACE2 – Design Considerations

BETonMACE2 is designed to expand on the original and incorporate a greater proportion of patients with high unmet need (specifically CKD patients)

The primary endpoint of BETonMACE2 will include hospitalization due to CHF alongside MACE



	Population	Primary Endpoint (PE)	Statistical Assumption	Interim analysis
BETonMACE	Post-ACS 7-90 days UA (25%) and MI (75%) Rosuvastatin or Atorvastatin (40-60%)	First occurrence of CV-death, non-fatal MI, non-fatal stroke	80% power to show 30% PE reduction at 5% alpha, i.e. 250 events	Planned but not performed
BETonMACE2	Post-ACS 7-90 days UA (25%) and MI (75%) SGLT2i (100%) CKD 25-30%	First occurrence of CV-death, non-fatal MI, hospitalization due to CHF	85% power to show 20% PE reduction at 5% alpha, i.e. 600 events	Interim analysis after approximately 300 events with stopping rule in place

Source: Company Management

Targeted - Global Development Plan

BETonMACE2 Estimated to cost $30-$35 million for Resverlogix[1]



Trial Size

3,600 patients
600 events

Basic Trial Design

- Type 2 Diabetes patients post ACS 7-180 days
- Study of patient sub-group with an estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m^2
- SGLT2 inhibitor if clinically indicated mandated for all subjects
- Endpoint, time to the first occurrence of narrowly defined MACE (CV death and MI) or hospital admission for CHF

Clinical Cost Est: $60-$70 million



[1] Total clinical cost of $60-$70 million with up to 50% of the trial to be conducted in China with costs to be paid by Shenzhen Hepalink Pharmaceutical "Hepalink"



Unique Dual Mechanism COVID-19 Program Update and Progress

COVID-19 Dual Mechanism Approach – ACE2 Reduction and Cytokine Storm Calming

RESVERLOGIX

Cell

Available online 16 March 2021

In Press, Journal Pre-proof

Article

BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection

Richard J. Mills [1], Sean J. Humphrey [2], Patrick RJ. Fortuna [1], Mary Lor [1], Simon R. Foster [1], Gregory A. Quaife-Ryan [1], Rebecca L. Johnston [1], Troy Dumenil [1], Cameron Bishop [1], Rajeev Rurarajuu [3, 4, 5], Daniel J. Rawle [1], Thuy Le [1], Wei Zhao [5], Leo Lee [5], Charley Mackenzie-Kludas [5], Neda R. Mehdiabadi [6], Christopher Halliday [7], Dean Gilham [7] ... James E. Hudson [1]

New Results

Comment on this paper

Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro

Dean Gilham, Audrey L Smith, Li Fu, Dalia Y Moore, Abenaya Muralidharan, St. Patrick M Reid, Stephanie C Stotz, Jan O Johansson, Michael Sweeney, Norman CW Wong, Ewelina Kulikowski, Dalia El-Gamal

doi: https://doi.org/10.1101/2021.03.10.432949

Targeting transcriptional regulation of SARS-CoV-2 entry factors *ACE2* and *TMPRSS2*

Yuanyuan Qiao[a,b,c,1], Xiao-Ming Wang[a,b,1], Rahul Mannan[a,b,1], Sethuramasundaram Pitchiaya[a,b], Yuping Zhang[a,b], Jesse W. Wotring[d], Lanbo Xiao[a,b], Dan R. Robinson[a,b], Yi-Mi Wu[a,b], Jean Ching-Yi Tien[a,b], Xuhong Cao[a,b,e], Stephanie A. Simko[a,b], Ingrid J. Apel[a,b], Pushpinder Bawa[a,b], Steven Kregel[a,b], Sathiya P. Narayanan[a], Gregory Raskind[a], Stephanie J. Ellison[a], Abhijit Parolia[a,b], Sylvia Zelenka-Wang[a,b], Lisa McMurry[a,b], Fengyun Su[a], Rui Wang[a], Yunhui Cheng[a], Andrew D. Delekta[a], Zejie Mei[f], Carla D. Pretto[g], Shaomeng Wang[a,c,d,g,h], Rohit Mehra[a,b,c,2], Jonathan Z. Sexton[d,g,i,j,2], and Arul M. Chinnaiyan[a,b,c,e,k,2,3]

COVID-19 Disease Progression – Unique Dual Mechanism



Apabetalone's dual mechanism makes it less reliant on ideal detection than current therapeutics

Source: CDC, Karolinska Institute

Cytokine Storm Pathways are Suppressed by Apabetalone Treatment

Hyperinflammatory Response Drives Negative Outcomes in COVID-19



Apabetalone Deactivates Hyperinflammatory Signaling Pathways



Pathway analysis visualization (Qiagen IPA) of SomaScan® plasma proteomic data (above) from chronic kidney disease (CKD) patients, demonstrates similar anti-inflammatory effects to those seen in cellular models of COVID-19

Source: Nature Publishing Group, Kidney International Reports

Key COVID-19 Trial Updates

Update 1	The active portion of the Covid-19 Trial has commenced – 14 patients being screened in Edmonton.	The UofA clinical facility began actively screening patients last week.
Update 2	Brazil is now fully approved	Full trial approval was received in Brazil early this week and apabetalone has now been shipped. Screening will commence there post the Christmas break.
Update 3	A prominent Infectious Disease Advisory Committee has been formed for the Covid-19 Phase 3 FDA trial.	The first meeting took place last week, Seven members participated, 3 are listed on the following slide with additional members securing their required institutional approvals.
Update 4	The Calgary clinical site has moved to the final Ethics Committee level.	A clinical site at UofC has moved forward, they will be the first group to apply for and use the joint Alberta/BC wide Ethics Committee approval.
Update 5	Arab sites completing preliminary work to join the trial.	Morocco has a lead to be first to join from Middle East as apabetalone is already labeled in French, one of the major languages in Morocco

COVID-19 Scientific Advisors

JUDITH S. CURRIER, MD

Professor of Medicine
Division Chief, Infectious Diseases
Director, UCLA Clinical AIDS Research and Education
UCLA Health
Los Angeles, California

CARLOS DEL RIO, MD

Executive Associate Dean
Distinguished Professor
Emory School of Medicine
Atlanta, Georgia

BARRY ZINGMAN, MD

Professor
Albert Einstein College of Medicine
Bronx, New York

RESVERLOGIX

Continued Unmet Need in COVID-19 Treatment

"Many of the drugs we will have available to treat ambulatory COVID-19 have only demonstrated antiviral activity, and they're likely only going to be effective in a select group of patients very early in the course of their infection. The morbidity and mortality resulting from COVID-19 infection are largely driven by the subsequent inflammatory response. Having a safe drug that shows activity against both viral infection and inflammation could be attractive. This dual mechanism of apabetalone could have more benefits potentially than other agents currently and soon to be available."

Barry S. Zingman, M.D.

Clinical Director, Infectious Diseases, Moses Division
Professor of Medicine, Albert Einstein College of Medicine

"While we have made good progress in the treatment of COVID-19, there is still a lot of room for improvement. We need effective and safe oral agents that can prevent worsening of the disease, especially one that can limit the amount of excessive inflammation that characterizes the main threat of COVID-19 infection to keep patients out of hospital, as well as alleviate the longer-term effects of the infection. The potential of apabetalone to fill that need is very promising."

Carlos del Rio M.D.

Distinguished Professor of Medicine Division of Infectious Diseases, Emory University School of Medicine;

Professor of Global Health and Epidemiology, Rollins School of Public Health. Atlanta, Georgia.

RESVERLOGIX

EVERSANA Partnership Update

Unique Dual Activity Targeting the COVID-19 Continuum



Source: Siddiqi. J Heart Lung Transplant. 2020;39:405., clinicaloptions.com

EVERSANA MANAGEMENT CONSULTING

RESVERLOGIX

EVERSANA Commercialization Partnership: Compressing Time



EVERSANA: Commercial Development Parallels Clinical

Regulatory Readiness in Canada

Initial discussions with Health Canada (HC) are underway to strengthen awareness of the active Phase 2 and Apabetalone.

Laying groundwork to engage with HC to be considered for NDS-Covid approval program, which provides an expedited authorization pathway using a rolling submission process.

Field medical operations in place to support HCP awareness and advocacy.

EVERSANA: Commercial Development Parallels Clinical

Pre-Trial Awareness for Global COVID-19 FDA Phase 3

Developing Resources to Engage Medical Community

Raising awareness with COVID-19 Specialists

Seeking Insights from COVID-19 Thought Leaders

Facilitating Onboarding for Clinical Trial Investigators

Formation of a Clinical Study Committee (CSC)

The CSC is an independent advisory board made up of internationally recognized researchers and specialists in infectious disease that supports RESVERLOGIX's COVID-19 clinical studies including trial design, data analysis and trial conduct

RESVERLOGIX

EVERSANA Provides Expansive Commercial Infrastructure and Experience



EVERSANA provides extensive commercialization infrastructure and experience through capital-efficient partnership

Partnership with EVERSANA Provides Complete Commercialization Support



End-to-end commercial strategy, operational excellence and a shared success delivery model:

- ✓ Minimize financial exposure
- ✓ Keep revenues
- ✓ Maintain full ownership

RESVERLOGIX

TSX: RVX

Resverlogix 2021 Clinical and Commercialization Update

December 16th 2021